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ABSTRACT
Purpose To measure the hydrodynamic radii of intravitreal
anti-VEGF drugs ranibizumab, aflibercept and bevacizumab
with μs time-resolved phosphorescence anisotropy.
M e t h o d s R u t h e n i u m - b a s e d d y e
Ru(bpy)2(mcbpy−O−Su−ester)(PF6)2, whose lifetime of several
hundred nanoseconds is comparable to the rotational correlation
time of these drugs in buffer, was used as a label. The hydrody-
namic radii were calculated from the rotational correlation times
of theRu(bpy)2(mcbpy−O−Su−ester)(PF6)2-labelled drugs ob-
tained with time-resolved phosphorescence anisotropy measure-
ments in buffer/glycerol solutions of varying viscosity.
Results The measured radii of 2.76±0.04 nm for
ranibizumab, 3.70±0.03 nm for aflibercept and 4.58
±0.01 nm for bevacizumab agree with calculations based on
molecular weight and other experimental measurements.
Conclusions Time-resolved phosphorescence anisotropy is a
relatively simple and straightforward method that allows exper-
imental measurement of the hydrodynamic radius of individual
proteins, and is superior to theoretical calculations which cannot
give the required accuracy for a particular protein.
KEY WORDS fluorescence . hydrodynamic radius .
phosphorescence . rotational diffusion . time-resolved anisotropy
ABBREVIATIONS
AMD Age-related macular degeneration
BSA Bovine serum albumin
DLS Dynamic light scattering
FCS Fluorescence correlation spectroscopy
FRAP Fluorescence recovery after photobleaching
MW Molecular weight
NMR Nuclear magnetic resonance
PBS Phosphate buffered saline
PLIM Phosphorescence lifetime imaging
SANS Small-angle neutron scattering
SAXS Small-angle x-ray scattering
VEGF Vascular endothelial growth factor
INTRODUCTION
There are many diseases that manifest in the posterior seg-
ment of the eye. These include age-related macular degener-
ation (AMD), retinal vein occlusion, and diabetic retinopathy
and maculopathy. Together they account for the majority of
blind registrations in the developed world (1). Many of these
diseases are treated with regular injections of drugs into the
vitreous cavity, with the inconvenience of regular clinic re-
view, cost of repeated injection, discomfort, and small but
repeated risks of complications (2). Given the many downsides
of regular intravitreal injections, the drug industry is actively
investigating novel methods of delivering drugs to the posteri-
or segment, including sustained release intravitreal devices (3),
transscleral drug delivery (4–6), topical drug delivery (eye
drops) (7), oral (8) and others such as iontophoresis (9).
Topical drug delivery has many potential advantages, in-
cluding self-administration, reduced cost, sustained drug
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levels, potentially fewer clinic visits, and the elimination of the
risks associated with eye injections. Whilst desirable, topical
drug delivery to the posterior segment is greatly impeded by
the external ocular barriers to diffusion. This is compounded
by the fact that many of the drugs used to treat posterior
segment disease have a high molecular weight (MW), includ-
ing ranibizumab (Lucentis®, 48 kDa), aflibercept (Eylea®,
97 kDa), and bevacizumab (Avastin®, 150 kDa).
Many factors, including the molecular size, charge, and
three-dimensional structure in the given environment, will
influence how intravitreal drugs cross the vitreous, and retina,
to reach diseased macular and choroidal tissue (10–12). It is
well known that increasing MW reduces diffusion across bio-
logical tissue (13–15), and other studies have shown that the
molecular radius is a better predictor of tissue penetration
than MW (4,5,15–18).
It is possible to estimate the radius of a protein from the
MW. Erickson uses the fact that all proteins have approxi-
mately the same density, 1.37 g/cm3, to calculate the protein
volume from the MW (19). Assuming a smooth spherical
shape, this yields a minimum possible radius
Rmin nmð Þ ¼ 0:066⋅MW1=3 ð1Þ
However, proteins have a rough surface, are often not per-
fectly spherical, and their charge can affect their diffusion in
solution. The hydrodynamic radius Rh, defined as the radius
of a hard sphere that diffuses at the same rate as the solute,
takes these effects into account. The hydrodynamic radius is
important in predicting transretinal penetration (5,20).
Small-angle scattering studies using X-rays (SAXS) or neu-
trons (SANS) (21) as well as dynamic light scattering (DLS)
(22,23) and nuclear magnetic resonance (NMR) techniques
(24) have been used for measuring Rh. Empirical relationships
have been defined between Rh and the number of amino acids
N (related to theMWbyN ¼ MW110 Da ), for example, byWilkins
et al. (24)
RWh åð Þ ¼ 4:75⋅N 0:29 ð2Þ
and Dill et al. (25)
RDh åð Þ ¼ 1:45⋅ 2:24⋅N 0:392
  ¼ 3:248⋅N 0:392 ð3Þ
These formulas were obtained by global analysis of hun-
dreds of proteins, and fitting to a scatter plot of Rh against
MW. While they give a good indication of the expected size,
there is a big variance in the measured Rh as a function of
MW. This can be explained by the deviation of these models
from the protein’s actual properties, which are due to molec-
ular shape, charge and surface roughness.
Time-resolved fluorescence or phosphorescence anisotropy
measurements can determine the molecule’s Brownian rota-
tional mobility which depends on the molecular volume and
the viscosity of the environment surrounding the molecule
(26). The sample is labelled with a fluorescent or phosphores-
cent dye, and excited with a pulse of polarised light. The
fluorescence or phosphorescence is collected in parallel and
perpendicular polarisation directions as a function of time.
The anisotropy r(t) of a molecule undergoing Brownian rota-
tional diffusion in solution can be obtained from the measured
intensities I∥ and I⊥ by
r tð Þ ¼ I tð Þ∥−GI tð Þ⊥
I tð Þ∥ þ 2GI tð Þ⊥
ð4Þ
where G is a correction factor that compensates for different
transmission and detection efficiencies in the parallel and the
perpendicular directions (27). If the sample solution contains
spherical molecules of homogeneous size, the anisotropy de-
cay follows a single-exponential function
r tð Þ ¼ r0⋅e− tϕ ð5Þ
where r0 is the initial anisotropy at t=0 and ϕ is the rotational
correlation time. If the rotating unit is not spherical, a more
complex multi-exponential model is required (28). ϕ can thus
be obtained by fitting Eq. 5 (or the more complex model) to
the experimental anisotropy decay. ϕ is related to the volume
V, and thus the effective radius, of the rotating molecule by the
Stokes-Einstein-Debye equation (29)
ϕ ¼ ηV
kT
ð6Þ
where η is the solvent viscosity, k is the Boltzmann constant
and T is the absolute temperature. Thus a plot of the rota-
tional correlation time ϕ versus the viscosity η should be a
straight line through the origin. The gradient should be V/
kT, and thus yield the volume of the rotating unit. Any possible
aggregation or preferential hydration would cause a deviation
of the graph from the linear model.
Although time-resolved anisotropy measurements are a
well established tool in molecular biology, only a few studies
report applications in ophthalmology (8,30). In this study the
effective hydrodynamic radii of three important posterior seg-
ment drugs—ranibizumab, aflibercept and bevacizumab—
were measured by μs time-resolved phosphorescence anisot-
ropy and compared to radii calculated from the MW. Due to
the large molecular weight of these drugs, short-lived nano-
second lifetime fluorescent dyes are not suitable for this study,
as the fluorescence will have decayed by the time the drug has
moved noticeably. Therefore, we used long-lifetime phospho-
rescence from a ruthenium-based dye (31) which allows us to
measure the rotational diffusion of molecules with large mo-
lecular weights (32,33). A well-characterised protein, bovine
serum albumin (BSA, MW=66.5 kDa, Rh=3.48 nm (34)),
was also measured as a reference to validate our results.
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METHOD
Reagents
Ranibizumab was purchased from Novartis (Frimley, UK)
(Lucentis® 10 mg/ml) and bevacizumab from Roche
(Welwyn Garden City, UK) (Avastin® 25 mg/ml). BSA was
purchased from Sigma (Poole, UK) at the highest available
purity. Aflibercept was purchased from Bayer plc (Newbury,
UK) as a 40 mg/ml solution (Eylea®). All other reagents were
of the highest available purity and were either from Sigma
(Poole, UK), VWR (Lutterworth, UK), or Merck
(Hoddesdon, UK) unless otherwise specified.
Sample Preparation
All protein solutions were diluted with sterile phosphate buff-
ered saline (PBS; Sigma; pH 7.4) to 5 mg/ml and then dia-
lyzed twice against PBS pH 7.4 using D-Tube Midi Dialyzer
units fromNovagen (6–8 kD cut-off). Subsequently, the purity
of the dialysed proteins was confirmed by standard SDS-
PAGE. The proteins were then conjugated to the ruthenium
dye. This was achieved by reacting the succinimidyl ester-
modi f i ed dye , B i s (2 ,2 ′ -b ipyr id ine ) -4 ′ -methy l -4 -
carboxybipyridine-ruthenium N-succinimidyl ester-
bis(hexafluorophosphate) (synonym, Ru(bpy)2(mcbpy−O
−Su− ester)(PF6)2, Sigma-Aldrich, MW=1 kDa) by using a
succinimidyl ester-modified fluorophore with a short linker
(Invitrogen, F6130). Conjugation reactions were performed
in PBS adjusted with bicine buffer to pH 8.6 at 2 mg/ml
protein concentration with the activated fluorophore ester be-
ing used in excess (2-fold and 3.5-fold for proteins >60 kD and
ranibizumab, respectively). The reaction was stopped after 2 h
and conjugated proteins were separated from remaining free
dye by size exclusion chromatography (two times via 7 kD cut-
off Zeba® spin columns (Thermo Fisher, UK)). Using this
method we generated the various proteins conjugated to the
fluorophore in the following dye:protein ratios: ranibizumab
1.1:1; BSA 1.2:1; aflibercept 1.8:1; bevacizumab 1.3:1, with
concentrations of 47 μM, 75 μM, 56 μM and 30 μM, respec-
tively. Azide (2.0 mM) was added to all dye-conjugated drugs
to protect them from microbial deterioration.
The isoelectric point (pI) is the pH at which a molecule
carries no net electrical charge, and is a major factor affecting
protein stability in solution. It is an intrinsic property of any
individual protein under the given conditions, and is the point
of least stability in solution. The isoelectric point of BSA at
25∘C is pH=4.7 (35). The theoretical isoelectric point of
aflibercept (Eylea) as calculated using ExPASy is 8.2. (web.
expasy.org) The isoelectric point of ranibizumab (Lucentis)
and bevacizumab (Avastin) was previously determined to be
8.8 (36,37). Our experiments were performed at pH=7.4,
which is a good compromise and far away from the pI values
of all compounds of interest and thus aggregation and precip-
itation are minimal under our conditions.
Anisotropy Measurements
TheRu(bpy)2(mcbpy−O−Su− ester)(PF6)2-labelled drugs in
buffer were mixed with glycerol in different proportions to
produce solutions with different viscosities up to ∼70% volume
fraction glycerol. 30 μl of each mixture was placed in a
multiwell plate with #1.5 coverslip glass bottom. The refrac-
tive index of each solution was measured with a refractometer
(Bellingham+Stanley, UK) before and after the phosphores-
cence measurement and converted to viscosity using a func-
tion fitted to a conversion chart (38).
A schematic diagram of the experimental setup is shown in
Fig. 1a. The anisotropy measurements were performed with a
Leica TCS SP2, a standard confocal inverted microscope,
equipped with a pulsed diode laser (PLP-10 470,
Hamamatsu, Japan; optical pulse width 90 ps) that served as
the excitation source (200 kHz repetition rate, 5 μs time inter-
val between pulses). The beam was focused in the middle of
the well containing the sample solution with a 20× NA 0.5 air
objective (Leica HC PL Fluotar). The emission was collected
with the same objective through a 550 nm long-pass emission
filter. A polariser was inserted in the emission path and paral-
lel and perpendicular polarisation components of the fluores-
cence emission were recorded sequentially with a hybrid de-
tector (HPM-100-40, Becker & Hickl GmbH, Berlin,
Germany) connected to a time-correlated single photon
count ing (TCSPC) acqu i s i t i on card (SPC 150 ,
Becker & Hickl GmbH, Berlin, Germany). The measurement
time window was 5 μs, with 4096 time channels and a cali-
bration of 1.22 ns/ch, and total data acquisition time of 30–
60 min per data set. A test measurement with short data
a b
c
Fig. 1 Illustration of the anisotropy measurements. (a) Schematic diagram of
the experimental setup. The sample, i.e. the drug in solution, was placed on a
confocal microscope stage and excited with a polarised pulsed laser. The
phosphorescence from the sample was reflected from a dichroic mirror
(DM) and recorded with a hybrid photodetector (HPD). (b) Schematic of
the phosphorescence decays at parallel and perpendicular polarisation, from
which the anisotropy (c) was calculated with Eq. 4.
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collection intervals confirms that bleaching does not cause
problems with the measurements, see Section S1.
Calculation of Hydrodynamic Radii
The anisotropies were calculated from the phosphorescence
intensity decays measured in parallel and perpendicular
polarisation directions with Eq. 4 (see Fig. 1b, c). The anisot-
ropies contain a fast component in addition to the expected
longer component and were fitted with gnuplot V4.6 (39) to a
double-exponential function:
y ¼ A1e−
t
ϕ1 þ A2e−
t
ϕ2 ð7Þ
where A1 and A2 are the amplitudes and ϕ1 and ϕ2 the rota-
tional correlation times of the two different components.
A plot of the longer rotational correlation time ϕ2 against
viscosity yields a straight line, from which the hydrodynamic
radius of the rotating unit can be calculated by combining the
Stokes-Einstein-Debye equation (Eq. 6) with the equation for
the volume of a sphere:
Rh ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
3kT
4π
ϕ2
η
3
s
ð8Þ
where k is the Boltzmann constant, T is the absolute temper-
ature and ϕ2/η is the gradient of the straight line.
RESULTS
T h e p h o s p h o r e s c e n c e l i f e t i m e o f t h e
Ru(bpy)2(mcbpy−O−Su− ester)(PF6)2 compound increases
with viscosity; examples of the measured raw decays are
shown in Fig. 2. The time-resolved anisotropy decays were
calculated according to Eq. 4, and representative examples
are shown in Fig. 3. The anisotropy decay time (i.e. the rota-
tional correlation time) increases with solvent viscosity for each
drug, as expected (Fig. 3). A double-exponential fit to the
anisotropy decay yields excellent fit results for all data sets;
the fit results are consistent and largely independent of starting
parameters and fitting range, and the residuals are flat without
systematic deviations. See Fig S4 for goodness of fit parame-
ters. Representative fits to three different viscosities for each
drug are shown in Fig. 3.
The shorter rotational correlation times,ϕ1, of the order of
a few ns, were too fast to be measured accurately due to the
long lifetime of the dye. The longer rotational correlation
times, ϕ2, corresponding to the drug’s rotational diffusion
were plotted against the viscosity, see Fig. 4. For each drug
this yields a straight line passing through the origin, as expect-
ed from Eq. 6, whose gradient depends on the molecular
volume. Gradients of 21.40±0.11 ns/cP for ranibizumab,
43.28±0.12 ns/cP for BSA, 51.47±0.12 ns/cP for aflibercept,
and 98.09±0.04 ns/cP for bevacizumab were obtained by
straight line fits according to Eq. 6 to the data sets using the
least squares method. Using Eq. 8, this yields experimental
hydrodynamic radii of 2.75±0.04 nm for ranibizumab, 3.49
±0.03 nm for BSA, 3.70±0.03 nm for aflibercept, and 4.58
±0.01 nm for bevacizumab. The theoretical radii of the drugs
were also calculated according to Eqs. 1, 2 and 3. A summary
of the calculated and measured hydrodynamic radii is shown
in Table I.
DISCUSSION
The radii obtained by anisotropy measurements are in the
expected range and consistent with calculations based on
MW, see Fig. 5, and our measured radius of 3.49±0.03 nm
a b
Fig. 2 Measured raw phosphorescence decays for aflibercept at two differ-
ent viscosities for parallel and perpendicular polarisation directions on a (a)
linear and (b) semilogarithmic scale.
Fig. 3 Example fits (lines) to measured anisotropy decays (data points) at
different viscosities. The rotational correlation time increases with viscosity,
and with the drug size. The decays were fitted with a double exponential
function (Eq. 7). The residuals are flat without systematic deviations, indicating
a good fit.
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excellent agreement with the accepted value of 3.48 nm (34).
While calculations based on the empirical formulas obtained
from the analysis of thousands of proteins can give a good
indication of the expected size, they cannot take into account
the properties of specific molecules relating to surface rough-
ness, shape, and the ionic charge which all affect the diffusion
of the molecule.
Time-resolved anisotropy measurements depend on the
volume of the compound undergoing Brownian rotational
diffusion according to Eq. 6. The rotational correlation time
depends on the cube of the radius, thus this technique is more
sensitive to small changes in radius than methods where the
radius depends on the measurement linearly, e.g. fluorescence
correlation spectroscopy (FCS) and fluorescence recovery af-
ter photobleaching (FRAP) or DLS.
Time-resolved anisotropy measurements can also give in-
formation about the shape of the molecule via the model used
to fit the decays, e.g. prolate and oblate ellipsoids of revolution
can in principle be discerned with this approach (26,28). The
anisotropies measured in this work are clearly double-
exponential: besides the component corresponding to the ro-
tation of the drug molecule, ϕ2, there is an additional fast
component, ϕ1. However, this fast component cannot be at-
tributed to non-spherical shape of the molecule; in case of an
ellipsoid, the anisotropy decay is three-exponential, but the
three exponentials are linked, and the fast component is too
fast to fit this model (26,28). While it is too fast to be measured
accurately with this method due to the long lifetime of the dye,
the results indicate a size comparable to the dye molecule
(MW=1 kDa), and thus this fast component ϕ1 is most likely
caused by the rotation of the dye molecule on its bond.
Wilkins et al. report a similar fast component (24). Double-
exponential fitting accounting for the fast component ϕ1 pro-
duces excellent fit results for our experimental data, where the
Brownian rotational motion of the drugs is represented by a
single slow component ϕ2, indicating that a spherical model
for the molecules is appropriate for our data analysis.
DLS, based on the measurement of fluctuating scattered
light intensity due to translational Brownian motion of the
particles, is a well-established method for determining the size
of small particles in solution, including macromolecular drugs
(40). With the compounds much smaller than the wavelength
of light, the light scattering is in the Rayleigh regime. To avoid
multiple scattering, low solute concentrations (generally
≲1 mg/ml) should be used, and the solvent must have a dif-
ferent refractive index than the compound, otherwise they are
Fig. 4 A plot of viscosity against rotational correlation timeϕ2 yields a straight
line passing through the origin for all data sets, as expected from Eq. 6. The
radius of the molecule can be calculated from the gradient with Eq. 8. The
error in the x-axis was derived from the uncertainty in the measured refractive
index, and the y-axis error from the uncertainty of the fit to the anisotropy
using standard error propagation.
Table I Summary of Hydrodynamic Radii Measured Experimentally (Rmeash ), Calculated with Empirical Formulas (Rmin, R
W
h and R
D
h ) and Reported DLS
Results (RWenDLS and R
Li
DLS )
Ranibizumab BSA Aflibercept Bevacizumab Equation Reference
MW (kDa) 48 66.5 115 149
Rmeash (nm) 2.75±0.04 3.49±0.03 3.70±0.03 4.58±0.01 8
Rmin (nm) 2.40 2.67 3.21 3.50 1 (19)
RWh (nm) 2.77 3.04 3.52 3.85 2 (24)
RDh (nm) 3.52 4.00 4.87 5.49 3 (25)
RWenDLS (nm) 4.2±0.3 5.4±0.1 – 6.3±0.1 – (42)
RLiDLS (nm) 4.1 4.8 – 6.5 – (36)
a b
Fig. 5 Comparison of hydrodynamic radii Rh measured experimentally
(black solid circles) with radii calculated from empirical formulas (lines) and
reported DLS results (hollow triangles) as a function of MW on a (a) linear
and (b) semilogarithmic scale.
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invisible (41). DLS can be sensitive to dust particles, but does
not require the compounds to be labelled with a dye, which
simplifies the sample preparation. No considerations about
the absorption spectrum of the dye, its emission spectrum
and its lifetime and how to link it to the compound are needed.
However, labelling the compound with a dye increases the
specificity of the measurement, as only the labelled
compound is measured, irrespective of its concentration, the
refractive index or ionic strength of the solution, or other
unlabelled solutes in the solution.
Wen et al. (42) report hydrodynamic radii of 4.2 nm for
ranibizumab and 6.3 nm for bevacizumab using DLS, and
5.4 nm for BSA measured as a control, and Li et al. (36) 4.1,
6.5 and 4.8 nm for the same molecules, respectively. These
results are slightly higher than estimates based on MW, and
higher than our results obtained with time-resolved phospho-
rescence anisotropy. Possible reasons could include aggrega-
tion, multiple scattering or a larger solvent cage that is
dragged around in translational diffusion.
SAXS and SANS are also popular methods for the size
measurement of macromolecules. While they can be used
with higher particle concentrations than DLS (∼1–100 mg/
ml) and are applicable to a largeMW range from a few kDa to
hundreds of MDa, they have low resolution, and structural
information can only be obtained through complex model
building (22). Similar to DLS, SAXS and SANS measure
scattering from unlabelled molecules which simplifies sample
preparation but makes the results susceptible to artefacts aris-
ing from dust and other contamination in the sample solution,
and makes these techniques impossible to be used with scat-
tering media, such as tissue.
The measurement time interval of 5 μs used in our exper-
iments is ideal for measuring the rotational correlation times
of these drugs with this ruthenium-based dye at low viscosities.
The detection volume could go down to the focal spot of a
scanning microscope operating at the optical diffraction limit,
and femtoliter volumes could be probed (43,44).
Due to the strong dependence of the rotational correlation
time on the molecular volume, see Eq. 6, anisotropy measure-
ments can be used to study binding or cleavage. Using a ge-
netically encoded probe with 13 ns fluorescence lifetime,
LUMP, it was shown that steady-state anisotropy measure-
ments could detect binding with CDC42 (32). DNA digestion
has also been monitored using fluorescently labelled DNA, as
indicated by a decrease in the anisotropy over time after ad-
dition of a DNA digesting enzyme (45). Moreover, when for-
mulating drugs, by addition of other components, sometimes
even other proteins, fluorescence or phosphorescence label-
ling before formulating would allow to specifically identify
and measure the protein of interest within a mixture.
If the long lifetime probe labelling approach is com-
bined with imaging, Phosphorescence Lifetime Imaging
(PLIM) (31,46) can be performed, either with scanning
confocal or wide-field microscopy. We have recently de-
veloped wide-field lifetime imaging approaches (47,48)
that are ideally suited for measuring microsecond life-
times, and could image several wells containing different
drugs and/or different viscosity solutions simultaneously.
If these microsecond-resolution wide-field time-correlated
single photon counting approaches were to be combined
with polarisation-resolved excitation and detection, one
could perform time-resolved anisotropy imaging (49) on
a microsecond time scale. This would benefit the mea-
surement of similar or higher MW drugs in several wells
of a multiwell plate simultaneously, and also enable imag-
ing these drugs in vitro. Alternatively, this approach could
be employed to map viscosity in cells (49,50).
CONCLUSION
Anisotropy measurements are commonly used in biochemical
applications to provide information on the volume of proteins,
as well as the viscosity of their surrounding environment. We
have shown that the hydrodynamic radii of anti-VEGF proteins
ranibizumab, aflibercept and bevacizumab can be measured
accurately using time-resolved anisotropy and a ruthenium-
based dye with a phosphorescence decay time of hundreds of
nanoseconds as a label. This relatively simple and straightfor-
ward approach allows the experimental measurement of the
hydrodynamic radius of individual proteins. It is superior to
theoretical estimations which cannot give the required accuracy
for a particular protein. Themeasured phosphorescence anisot-
ropy decays are double-exponentials, with a long component
caused by the Brownian rotational diffusion of the drug mole-
cule, and a short component due to the dye rotating on its
bond. The measurement of well-characterised protein BSA as
a reference confirms the validity of this approach. The experi-
mental radii for BSA, ranibizumab, aflibercept and
bevacizumab are in good agreement with the radii calculated
from molecular weight and other experimental measurements.
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